NCT03721705 - Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type | Biotech Hunter

Enrollment

190

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

March 23, 2021

Study Completion Date

March 23, 2021

Conditions

Alzheimer DiseaseCognitive DysfunctionMild Cognitive ImpairmentMild DementiaCognitive DeclineDementia, Alzheimer Type

Interventions

DEVICE

Renew NCP-5

Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.

Trial Locations (12)

iResearch Atlanta, Atlanta

iResearch Savannah, Savannah

Charter Research, Lady Lake

Miami Dade Medical Research Institute, Miami

Neuro-Behavioral Clinical Research, Canton

University of Kansas Medical Center, Kansas City

Cardiovascular Advantages, LLC, Baton Rouge

Xenoscience, Phoenix

Irvine Clinical Research, Irvine

Northwest Clinical Research Center, Bellevue

St. James's Hospital, Dublin

National University Hospital, Singapore